DFS vs PLX
DFS (DFS) versus Protalix Biotherapeutics Inc (PLX) — a side-by-side from cached financials, not a winner call.
DFS (DFS) common stock.
Protalix Biotherapeutics Inc (PLX) is a biotechnology company listed on US.
DFS does not have a complete income-statement cache yet.
Latest reported PLX revenue for 2024-12-31 was $53.4M. Net income was $2.9M. Revenue was down 18.5% from 2023-12-31 to 2024-12-31. PLX currently screens at market cap $122.6M and trailing P/E 30.8.
PLX currently screens at market cap $122.6M and trailing P/E 30.8.
Not investment advice. Open the DFS and PLX stock pages for the full models.
Not investment advice.